BJMO - volume 17, issue 7, november 2023
J. Blokken PhD, PharmD
In this section of the BJMO, we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on oncology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjmo.be) and we will make sure to include it in the journal scan section of the next BJMO issue.
(BELG J MED ONCOL 2023;17(7):271–4)
Read moreBJMO - volume 17, issue 6, october 2023
J. Blokken PhD, PharmD
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J MED ONCOL 2023;17(6):245)
Read moreBJMO - volume 17, issue 6, october 2023
A. Enguita PhD, J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the BJMO, we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on oncology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjmo.be) and we will make sure to include it in the journal scan section of the next BJMO issue.
(BELG J MED ONCOL 2023;17(6):239–44)
Read moreBJMO - volume 17, issue 5, september 2023
J. Blokken PhD, PharmD
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J MED ONCOL 2023;17(5):156)
Read moreBJMO - 2023, issue Special, july 2023
J. Blokken PhD, PharmD
Besides interesting data on novel treatment options for melanoma patients, the 19th European Association of Dermato-Oncology (EADO) congress featured several sessions on non-melanoma skin cancer. Below, we give an overview of recent advances in cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC) and Merkel Cell Carcinoma (MCC), as well as some promising new treatment strategies and combinations.
Read moreBJMO - 2023, issue Special, july 2023
J. Blokken PhD, PharmD
Melanoma is the third cause of central nervous system (CNS) metastases and roughly 40–50% of advanced melanoma patients will develop CNS metastases. Importantly, the incidence of brain metastases may rise even further as systemic treatment of stage IV melanoma improves. In addition, CNS metastases are more frequent in BRAF-mutated melanoma. Finally, as responses in intracranial vs. extracranial sites may be heterogeneous, the efficacy of systemic therapy on brain metastases may be difficult to predict.1–4 Although the clinical survival outcomes of melanoma patients with brain metastases have been significantly improved due to major advances in systemic therapy, there still remain to be many challenges.
Read moreBJMO - 2023, issue Special, july 2023
A. Enguita PhD, J. Blokken PhD, PharmD
The 2023 annual European Association of Dermato-Oncology (EADO) congress featured exciting developments in melanoma research. In the adjuvant setting, discussions centred around new biomarkers for treatment response, the role of radiotherapy and new approaches in immunotherapy. Interesting updates were also presented for the treatment of metastatic melanoma, including triple combinations of BRAF plus MEK inhibitors (BRAFi/MEKi) with immune checkpoint inhibitors (ICIs), an IDO/PD-L1-targeting peptide vaccine with nivolumab, and AS01B with myeloid dendritic cells and ICIs.
Read moreTo provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.